3-hydroxymethyl-valeric acid | 81381-86-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-hydroxymethyl-valeric acid
• 英文别名: 2-Oxymethyl-butan-carbonsaeure-(1)；3-Hydroxymethyl-valeriansaeure；β-(Oxymethyl)-butan-α-carbonsaeure；γ-Oxy-β-aethyl-buttersaeure；3-Methylol-pentansaeure-(1)；3-ethyl-4-hydroxybutanoic acid；3-Hydroxymethyl-pentanoic acid；3-(hydroxymethyl)pentanoic acid
• CAS: 81381-86-4
• 化学式: C₆H₁₂O₃
• mdl: MFCD19228740
• 分子量: 132.159
• InChiKey: LWORUNAJLBJFRG-UHFFFAOYSA-N

物化性质

• 沸点：
  280.4±23.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-乙基四氢呋喃-2,5-二酮 在 乙醚 、 aluminium amalgam 作用下， 生成 3-hydroxymethyl-valeric acid
  参考文献：
  名称：

  Fichter; Beisswenger, Chemische Berichte, 1903, vol. 36, p. 1200

  摘要：

  DOI：

文献信息

• Energy substrate containing hydroxycarboxylic acid and a glycerol ester
  申请人：KABIVITRUM AB

  公开号：EP0367734A1

  公开（公告）日：1990-05-09

  An energy substrate for administering nutrient to mam­mals in a catabolic state is characterised in that it contains at least one ester of glycerol and at least one hydroxy carboxylic acid having a branched carbon chain.

  一种用于给处于分解代谢状态的哺乳动物提供营养的能量底物，其特征在于它含有至少一种甘油酯和至少一种具有支链碳链的羟基羧酸。
• Energy substrate containing hydroxycarboxylic acid
  申请人：KABIVITRUM AB

  公开号：EP0363337A1

  公开（公告）日：1990-04-11

  The invention relates to an energy substrate for nutrient administration to mammals in a catabolic state, and includes at least one hydroxy carboxylic acid of the general formula wherein R₁ is hydrogen or straight or branched alkyl or alkenyl and R₂ is straight or branched alkyl or alkenyl, wherein when R₁ is hydrogen, R₂ will always be branched alkyl or alkenyl, wherein R₁ and R₂ together contain from 2 to 6 carbon atoms, n is zero or 1, and A is hydrogen or a pharmaceutically acceptable metal cation.

  本发明涉及一种用于给处于分解代谢状态的哺乳动物提供营养的能量底物，包括 至少一种通式如下的羟基羧酸 其中 R₁ 是氢或直链或支链烷基或烯基，R₂ 是直链或支链烷基或烯基，当 R₁ 是氢时，R₂ 总是支链烷基或烯基，其中 R₁ 和 R₂ 共含有 2 至 6 个碳原子，n 是 0 或 1，A 是氢或药学上可接受的金属阳离子。
• Tricyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0826686A2

  公开（公告）日：1998-03-04

  A pharmaceutical composition for treating or preventing proliferative glomerulonephritis, which comprises a compound of the formula: wherein ring A is a nitrogen-containing heterocyclic ring, having two nitrogen atoms as the hetero-atoms, which may be substituted with oxo or thioxo; ring Q may be substituted; Y is an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted mercapto group; and R1 is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group or an acyl group, or a salt thereof, and a novel compound of the formula: wherein ring Aa may have one oxo group; D is a bond or an optionally substituted divalent hydrocarbon group; ring W is an optionally substituted nitrogen-containing heterocyclic ring; ring Q may be substituted; and R3 is an electron-withdrawing group, or a salt thereof, which have excellent PDGF-inhibiting activities, activities of ameliorating renal diseases and activities of lowering lipid level and are less toxic and are useful as a preventive and treating agent for cardisvascular diseases.

  一种用于治疗或预防增殖性肾小球肾炎的药物组合物，其中包含一种式化合物： 其中环 A 是含氮杂环，具有两个氮原子作为杂原子，可被氧代或硫代取代；环 Q 可被取代；Y 是任选取代的烃基、任选取代的羟基或任选取代的巯基；以及 R1 是氢原子、卤素原子、任选取代的烃基或酰基，或其盐，以及式中的新型化合物： 其中环 Aa 可以有一个氧代基团； D 是键或任选取代的二价烃基； 环 W 是任选取代的含氮杂环；环 Q 可被取代；以及 R3 是取电子基团或其盐，它们具有优异的 PDGF 抑制活性、改善肾脏疾病的活性和降低血脂的活性，且毒性较低，可用作心血管疾病的预防和治疗剂。
• Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
  申请人：Eupraxia Pharmaceuticals USA LLC

  公开号：US11219604B2

  公开（公告）日：2022-01-11

  Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant.

  本文描述的是可注射的皮质类固醇微颗粒、其药物组合物以及用于减轻关节、硬膜外腔、眼球玻璃体、手术形成的腔隙或邻近植入物的腔隙等身体部位的炎症或疼痛的方法。
• The Kinetics of Esterification and of Catalytic Hydrogenation of the Furoic and Furanacetic Acids
  作者：Hilton A. Smith、James B. Conley、W. Holmes King

  DOI：10.1021/ja01154a040

  日期：1951.10